Arrowhead (ARWR) Pharmaceuticals announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference, RNAi, therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Strong Buy Rating Backed by Promising RNAi Pipeline and Strategic Partnerships
- Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Biotech Alert: Searches spiking for these stocks today
- Arrowhead price target lowered to $63 from $71 at UBS
- Arrowhead Pharmaceuticals: Strong Financial Position with Pipeline Uncertainties Justifying Hold Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue